Today's Date: March 4, 2021
IMAX China Reports Full-Year 2020 Financial Results   •   Gillette® Announces the Return of the Gillette Gaming Alliance   •   Jazwares Extends Wildly Popular Squishmallows® Brand With The Launch Of Squishville™   •   SoleSavy Hires Former Los Angeles Lakers Head of Marketing as Senior Vice President of Marketing   •   Xfinity Communities Offers Riverside Foundry Residents High Performance WiFi Ready Experience   •   CNNBS Announces New Partnership With Baroni Cannabis   •   Sight Sciences Receives FDA Clearance for Expanded Indication for OMNI Surgical System   •   Society for Immunotherapy of Cancer to Host Virtual Leadership Institute Focusing on Professional Development of Women in Cancer   •   Stacey Abrams Urges Women to Champion Change for Those Who Need it Most at the California Conference for Women   •   Top LA Agency, Westside Nannies, Voices Concerns Over Nannies Being Excluded from Vaccine Phase 1B   •   Novetta Success Hiring U.S. Military Service Members with DoD SkillBridge Program   •   Innovative Procedures Allow Identical Twin to Donate to Her Sister's Breast Reconstruction   •   Dr. Anthony Bared Takes Part in Facial Hair Transplantation for Transgender Patients Study   •   Five Termite Species All Homeowners Should Be Aware Of   •   Subsplash Messaging Provides a Compelling Alternative to GroupMe & Slack for Churches   •   PGMA Safety Campaign Warns of Carbon Monoxide Dangers With Portable Generator Misuse   •   CORRECTING and REPLACING Micro-Mobility Leader, Helbiz, Launches E-Scooters in Jacksonville, Florida   •   Study Shows SARS-CoV-2 Virus Not Detected in Human Semen   •   The Change Company Names B.C. Silver President of Digital Banking   •   Secret Deodorant Brings Relief to Over 100,000 Women and Their Families with YWCA Partnership
Bookmark and Share

CHOP Researchers Find NTRK Fusions More Common than Expected in Pediatric Tumors

CHOP Researchers Find NTRK Fusions More Common than Expected in Pediatric Tumors

--Study highlights wide range of pediatric cancers in which NTRK fusions are more likely to occur, which could help prioritize testing for targeted treatment with FDA-approved TRK inhibitors--

PR Newswire

PHILADELPHIA, Jan. 15, 2021 /PRNewswire/ -- In a large study of pediatric cancer patients, researchers from Children's Hospital of Philadelphia (CHOP) have analyzed the frequency, fusion partners, and clinical outcome of neurotrophic tyrosine receptor kinase (NTRK) fusions, which are clinical biomarkers that identify patients suitable for treatment with FDA-approved TRK inhibitors. The researchers found that NTRK fusions are more common in pediatric tumors and also involve a wider range of tumors than adult cancers, information that could help prioritize screening for NTRK fusions in pediatric cancer patients who might benefit from treatment with TRK inhibitors.

The findings were published in JCO Precision Oncology.

"Our findings demonstrate that NTRK fusions are far more frequently seen in pediatric tumors than in adult tumors and involve a broader panel of fusion partners and wider range of pediatric tumors than previously recognized," said senior author Marilyn M. Li, MD, Vice Chief of the Division of Genomic Diagnostics and Director of Cancer Genomic Diagnostics at CHOP. "With the recent FDA approval of larotrectinib and entrectinib for the treatment of adult and pediatric NTRK-positive, unresectable solid tumors, identification of these fusions directly impacts patient care."

Previous studies have shown that rearrangements of NTRK genes drive tumor growth in a diverse range of cancers. This led to the development of the first generation oral NTRK inhibitors, larotrectinib and entrectinib, and have spurred the development of other NTRK inhibitors, which are currently in clinical development. Ongoing clinical trials hope to identify optimal use of these drugs in children.

Given that in children, certain cancers like infantile fibrosarcoma (IF) and secretory carcinoma have very high incidence of NTRK fusions (>90%), whereas other cancers like melanoma and acute leukemia rarely involve NTRK fusions, the researchers sought to better understand the frequency of these gene fusions across all pediatric cancers.

To do so, they analyzed 1,347 consecutive pediatric tumors from 1,217 patients who underwent tumor genomic profiling using custom-designed DNA and RNA next generation sequencing panels. The researchers identified NTRK fusions in 29 tumors from 27 patients, with a positive yield of 2.22% for all tumors and 3.08% for solid tumors. NTRK fusions were detected in 13% of papillary thyroid carcinomas (PTCs), 1.9% of central nervous system (CNS) tumors, 1.8% of non-CNS, non-PTC solid tumors, and 0.4% of hematologic malignancies.

Patients in the study were followed for up to 46 months, and in almost all cases, the detection of an NTRK fusion confirmed the diagnosis of the lesion type, including five cases where the final tumor diagnosis was largely based on the discovery of an NTRK fusion. In one patient, the diagnosis was changed due to the identification of an NTRK fusion. In a separate case, a 6-month-old infant with a mass in his upper left extremity due to IF, which would have required extremely complex surgery to remove, was treated with larotrectinib and achieved complete pathologic remission.

"The identification of these NTRK fusions has facilitated precision cancer diagnosis and TRK inhibitor targeted therapy," Li said. "Our experience highlights the clinical utility of screening NTRK fusions for all pediatric tumors."

This study was partially supported by the NIH (U2CHL138346).

Zhao et al. "NTRK Fusions Identified in 1,217 Pediatric Tumors: the Frequency, Fusion Partners, and Clinical Outcome," JCO Precision Oncology, online January 14, 2021, DOI: 10.1200/PO.20.00250

About Children's Hospital of Philadelphia: Children's Hospital of Philadelphia was founded in 1855 as the nation's first pediatric hospital. Through its long-standing commitment to providing exceptional patient care, training new generations of pediatric healthcare professionals, and pioneering major research initiatives, Children's Hospital has fostered many discoveries that have benefited children worldwide. Its pediatric research program is among the largest in the country. In addition, its unique family-centered care and public service programs have brought the 595-bed hospital recognition as a leading advocate for children and adolescents. For more information, visit http://www.chop.edu

Contact: Ashley Moore

Children's Hospital of Philadelphia

(267) 426-6071

Moorea1@chop.edu

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/chop-researchers-find-ntrk-fusions-more-common-than-expected-in-pediatric-tumors-301209371.html

SOURCE Children's Hospital of Philadelphia



Back to top
| Back to home page
Video

White House Live Stream
LIVE VIDEO EVERY SATURDAY
alsharpton Rev. Al Sharpton
9 to 11 am EST
jjackson Rev. Jesse Jackson
10 to noon CST


Video

LIVE BROADCASTS
Sounds Make the News ®
WAOK-Urban
Atlanta - WAOK-Urban
KPFA-Progressive
Berkley / San Francisco - KPFA-Progressive
WVON-Urban
Chicago - WVON-Urban
KJLH - Urban
Los Angeles - KJLH - Urban
WKDM-Mandarin Chinese
New York - WKDM-Mandarin Chinese
WADO-Spanish
New York - WADO-Spanish
WBAI - Progressive
New York - WBAI - Progressive
WOL-Urban
Washington - WOL-Urban

Listen to United Natiosns News